#United States #Atlanta #GRIN Therapeutics #Radiprodil #Neurodevelopmental Disorders

GRIN Therapeutics' Highlighted Presentation at the AES Annual Meeting

GRIN Therapeutics, Inc., recognized for its pioneering work in targeted treatments for serious neurodevelopmental disorders, is geared up to present significant insights at the upcoming American Epilepsy Society (AES) Annual Meeting. This year's event is scheduled from December 5 to 9, 2025, in Atlanta, GA, and promises to showcase revolutionary methodologies in clinical trial assessments.

The primary focus of GRIN Therapeutics' presentation will be on their ambitious global Phase 3 Beeline clinical trial for their investigational therapy, radiprodil. This particular study is crucial for patients suffering from GRIN-related neurodevelopmental disorders (GRIN-NDD). The session will feature the unveiling of novel Clinical Global Impression scales, specifically designed to track the severity and progression of symptoms that are characteristic of GRIN-NDD.

Importance of the Presentation

The inclusion of customized outcome measures such as the Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Change (CGI-C) seeks to better reflect the experience of both patients and their caregivers. These new tools are expected to accurately measure significant changes in symptoms and overall quality of life, aiming to provide a deeper understanding of how treatments like radiprodil impact daily functioning.

Russell L. Chin, MD, the Medical Director at GRIN Therapeutics, will spearhead the presentation, scheduled for December 9 from 12:00 to 1:45 PM EST. His insights aim to bridge the gap between innovative treatment protocols and practical applications in clinical settings.

Understanding Radiprodil

Radiprodil is notable as a potent negative allosteric modulator specifically aimed at the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, a target linked to multiple neurodevelopmental disorders. Its potential has been recognized through multiple designations by regulatory authorities, including Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease statuses from the U.S. Food and Drug Administration.

This ongoing commitment to advancing treatments means that radiprodil is not only being evaluated for GRIN-NDD but is also under investigation for other conditions such as tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. The Astroscape trial currently assesses the drug's safety and efficacy, building a solid foundation for its anticipated impact on patient care.

Future Endeavors and Company Background

GRIN Therapeutics is dedicated to the mission of delivering precision therapies, driven by a vision of transforming the landscape of treatment for neurodevelopmental disorders. Recent achievements, including promising outcomes from the Honeycomb Trial, have encouraged the company to transition into a global pivotal Phase 3 trial program for radiprodil, marking a significant step forward for both the company and patients in need of effective interventions.

As part of the larger Neurvati Neurosciences initiative, backed by Blackstone Life Sciences, GRIN Therapeutics continues to leverage extensive resources and expertise to expedite the process of bringing much-needed therapies to those affected by complex neurological conditions. The AES Annual Meeting represents an invaluable opportunity for GRIN Therapeutics to share their findings with the medical community, further fostering advancements in the field of neurology.

Conclusion

The upcoming AES Annual Meeting is poised to be an essential platform for GRIN Therapeutics, showcasing their innovative approaches to both research and treatment evaluation. By presenting their developments in clinical outcome measures, the company aims to contribute significantly to the understanding and treatment of neurodevelopmental disorders, while also paving the way for future therapies that could change lives worldwide.